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Abstract: The progressive nature of type 2 diabetes poses challenges in the clinic: treatment 
must be continually reviewed and adjusted in response to the patient’s changing pathophysiology. 
Ultimately, insulin replacement therapy will be necessary as the physiological insulin response 
is compromised. The modern basal insulin analog insulin detemir has been the subject of several 
clinical trials and observational studies in type 2 diabetes. Compared with NPH insulin, insulin 
detemir offers an improved balance between achieving current glycemic targets with acceptable 
tolerability. Insulin detemir also has a unique weight-sparing effect which is associated with 
body mass index, and this may be a particular advantage to obese patients with type 2 diabetes. 
This review summarizes data from key clinical studies of insulin detemir, and also provides 
insights from observational studies.
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Introduction
At least 246 million people worldwide (age group 20–79 years) have diabetes (IDF 
2006). For type 2 diabetes (the more common form of the disease) sedentary lifestyles, 
poor diets and aging populations are thought to contribute to the growing epidemic. 
In particular, the number of people with obesity is escalating, which poses a major 
risk factor for the onset type 2 diabetes (WHO 2008).
Type 2 diabetes is a metabolic disorder characterized by relative insulin deﬁ  ciency 
resulting from a reduced sensitivity of tissues to insulin and impairment of insulin 
secretion from pancreatic beta-cells. This leads to chronic hyperglycemia with distur-
bances of carbohydrate and other nutrient metabolism, all of which increase the risk of 
health complications in the future (UKPDS 33 1998; UKPDS 35 2000). Complications 
such as cardiovascular disease account for 30%–50% of mortality amongst people 
with diabetes, and diabetic neuropathy and retinopathy are frequent morbidities in this 
patient group (UKPDS 33 1998; UKPDS 35 2000). Modern therapies aim to achieve 
levels of glycemic control close to those found in health, in order to reduce the risk 
of these complications.
Initially, treatment for type 2 diabetes relies on diet and lifestyle changes; metformin 
can be added quickly if there is no preliminary response. As the disease progresses, 
oral antidiabetic drugs (OADs) are administered, ﬁ  rst as monotherapy, and later, as the 
condition progresses, as combination therapy using two or three OADs with additive or 
synergistic potential. However, many type 2 diabetes patients will still require insulin 
to maintain good glycemic control (Figure 1). Some authors have suggested initiating 
insulin early in the treatment paradigm (Nathan et al 2006) in order to maintain good 
glycemic control (HbA1c   7%) and also to preserve beta-cell function, which is pro-
gressively diminished by over-exposure to hyperglycemia (Buchanan 2003).Patient Preference and Adherence 2008:2 324
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Barriers to the initiation 
of insulin therapy
Despite the demonstrated benefits of initiating insulin 
therapy, there is often considerable resistance from both 
patients and physicians. Patients tend to feel apprehensive 
about injections, as they are perceived by many to be invasive 
and painful (Korytkowski 2002). This misconception may, 
in part, have been fostered by past experiences with older 
delivery systems such as syringes and vials.
Patients may also be anxious about hypoglycemia and 
weight gain, which are well recognized adverse effects 
associated with insulin therapy. These apprehensions are 
likely to negatively inﬂ  uence the prescribing attitudes of 
physicians towards insulin regimens (Korytkowski 2002; 
Home et al 2003; Davies 2004). This issue is highlighted by 
the Diabetes Attitudes Wishes and Needs (DAWN) study, a 
survey of health care professionals (nurses = 1,109; physi-
cians = 2,681) and insulin-naïve people with diabetes (2,061) 
in 13 countries. The DAWN study reported that many health 
care providers, especially those in the USA, are inclined to 
delay initiation of insulin therapy as a result of concerns 
over patient adherence to an insulin-based regimen (Peyrot 
et al 2005).
Attitude-related barriers to insulin use are commonly 
referred to as ‘psychological insulin resistance’, which not 
only delays insulin initiation when blood glucose control 
worsens, but can also restrict insulin intensiﬁ  cation, a modi-
ﬁ  cation required as the disease state progresses and beta-cell 
function deteriorates. Failure to initiate or intensify insulin 
in a timely fashion can have serious consequences, as even 
brief periods of poor glycemic control in individuals with 
type 2 diabetes ultimately increase the risk of micro- and 
macrovascular complications (UKPDS 35 2000).
Insulin detemir: designed to support 
patient acceptance of basal insulin
For many years, insulin therapy in type 2 diabetes has made 
use of older basal insulins such as neutral protamine Hagedorn 
(NPH) insulin. There are, however, important disadvantages 
with NPH insulin, in particular a short duration of action 
(less than 24 hours) (Lepore et al 2000), large variability 
in the glucose-lowering effect from injection to injection, 
and a pronounced peak activity in effect (Heise et al 2004). 
Within-subject variability of the pharmacodynamic effect 
may affect the extent to which blood glucose levels ﬂ  uctuate 
in individual patients (Heise et al 2004). Superimposed on a 
peak effect around 4 hours after dosing followed by a decline 
(Heise and Pieber 2007), this variability translates into a 
major contributing factor to nocturnal hypoglycemia.
Insulin analogs have been engineered by adapting the 
human insulin molecular structure, with the aim of provid-
ing a more physiological insulin proﬁ  le than exogenous 
human insulin in patients with diabetes. In particular, the 
amino acid sequence and physicochemical properties have 
been modiﬁ  ed with an aim to overcome the pharmacokinetic 
shortcomings of exogenous human insulins. This, in turn, is 
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intended to improve the balance between glycemic control 
and tolerability (Gough 2007; Heller et al 2007).
Unlike NPH insulin, insulin detemir’s prolonged absorp-
tion proﬁ  le is not achieved by the resuspension of crystals 
with subsequent dissolution in the subcutaneous tissue; 
neither, unlike insulin glargine, does it rely on the dissolu-
tion of microprecipitates formed after injection (Klein et al 
2007). Instead, the prolonged absorption of insulin detemir is 
established by its self-association into stable hexamers, and 
the apparent ability of these to aggregate to form dihexamers 
when in high concentrations, such as in the subcutaneous 
injection site (Havelund et al 2004). Furthermore, insulin 
detemir has an acylated fatty acid chain that enables revers-
ible binding to albumin at the injection depot. In the circula-
tion, albumin binding also buffers the effect of changes in the 
absorption rate from the injection site, thereby contributing to 
reduced pharmacodynamic variability (Havelund et al 2004; 
Kurtzhals 2004). As a result, insulin detemir has a long and 
relatively ﬂ  at time–action proﬁ  le, which is consistent from 
one injection to another in comparison with NPH insulin and 
insulin glargine (Heise et al 2004; Klein et al 2007). This 
has recently been demonstrated in a cohort of patients with 
type 1 diabetes who were randomized to receive injections 
of insulin detemir or insulin glargine (Bock et al 2008). The 
authors concluded that an action proﬁ  le of approximately 
24 hours in the majority of patients made both insulins suit-
able for once-daily dosing, and a lower variation between 
injections was observed for patients randomized to insulin 
detemir (Bock et al 2008).
The pharmacodynamic properties of insulin detemir 
have been investigated in a series of glycemic clamp studies. 
Heise et al (2004) reported greater consistency in the glucose 
infusion rate time curves in patients with type 1 diabetes 
administered insulin detemir in a repeat clamp study, and 
this was reﬂ  ected in the lower coefﬁ  cients of variability in 
numerous pharmacodynamic endpoints. Signiﬁ  cantly lower 
within-subject variability was demonstrated (as deﬁ  ned by 
coefﬁ  cient of variation of glucose infusion rate, area under 
curve) with insulin detemir compared with NPH insulin and 
insulin glargine: 27% vs 34% vs 46%, respectively (Heise 
et al 2004). Klein et al (2007) reported similar ﬁ  ndings in 
patients with type 2 diabetes as within-subject variability 
was found to be signiﬁ  cantly lower for the albumin-bound 
insulin analogs insulin detemir and an experimental acylated 
analog, NN344, than insulin glargine (Klein et al 2007). This 
suggests the lower within-subject variability observed with 
insulin detemir may be an inherent property of its ability to 
bind to albumin. (Heise and Pieber 2007; Klein et al 2007).
Safety proﬁ  le of insulin detemir
Molecular alteration of human insulin to form insulin analogs 
can compromise binding properties, and also the metabolic 
and mitogenic potencies associated with endogenous human 
insulin, since this peptide hormone also has some afﬁ  nity for 
the insulin-like growth factor I (IGF-I) receptor, which is 
associated with stimulation of mitosis. In vitro studies have 
demonstrated that the mitogenic potency of insulin analogs 
mostly correlates with their relative IGF-I receptor binding 
afﬁ  nities and/or their rate of dissociation from the insulin 
receptor; analogs with high afﬁ  nity for the IGF-I receptor 
and/or a low dissociation rate from the insulin receptor 
have increased mitogenic potency. Lessons learned from the 
toxicological implications of the insulin analog, B10Asp, an 
analog whose mitogenic potency was high, have informed 
the development of subsequent insulin analogs (Kurtzhals 
et al 2000). Insulin detemir has been shown to have a low 
mitogenic potential and a low IGF-I receptor afﬁ  nity com-
pared with human insulin (Kurtzhals et al 2000).
Albumin-binding has also been researched to conﬁ  rm 
safety; no drug interactions involving other albumin-binding 
drugs have been identiﬁ  ed, while the number of fatty acid 
binding sites available in circulating albumin exceed the 
number required for a therapeutic dose of insulin detemir 
(with a molar concentration in serum of only 1:50,000 to 
that of albumin) (Home and Kurtzhals 2006).
Advantages of insulin detemir 
in the clinical arena
Multicenter, open-label, parallel, randomized clinical phase III 
studies of 22–104 weeks in duration were conducted to com-
pare the effect of insulin detemir, NPH insulin and insulin 
glargine on glycemic control, hypoglycemia and weight.
Improving glycemic control and reducing 
hypoglycemic risk
Randomized controlled trials have established insulin 
detemir to be as effective as NPH insulin (in both basal 
plus OAD therapy and basal plus bolus therapy) and insulin 
glargine (in basal plus OAD therapy) in improving glycemic 
control in type 2 diabetes (Rašlová et al 2004; Haak et al 
2005; Hermansen et al 2006; Philis-Tsimikas et al 2006; 
Rosenstock et al 2008). Trials using aggressive ’treat-to-
target’ dose titration algorithms have found that the addition 
of insulin detemir to oral drug therapy in patients failing on 
OADs alone can reduce mean HbA1c values in people with 
type 2 diabetes by approximately 1.5% (Hermansen et al 
2006; Philis-Tsimikas et al 2006; Rosenstock et al 2008). Patient Preference and Adherence 2008:2 326
Philis-Tsimikas
Thus, if baseline HbA1c is not already elevated above 8.5%, 
the achievement of guideline targets can be expected in 
many individuals.
Hermansen et al (2006) reported a treat-to-target study 
comparing twice-daily insulin detemir with twice-daily NPH 
insulin in basal insulin plus OAD regimens.
In this 26-week, parallel-group, multicenter trial, 
475 patients were randomized to treatment with insulin 
detemir or NPH insulin, adjusted to reach pre-breakfast and 
pre-dinner plasma glucose targets of   6 mmol/L.
Patients from each treatment arm experienced similar 
reductions and improvements in HbA1c; this corresponded 
to a ﬁ  nal mean HbA1c of 6.8% with insulin detemir and 6.6% 
with NPH insulin, with a large proportion of all patients 
(70%) reaching their target HbA1c of   7.0%. Moreover, 
the number of patients reaching this target without hypogly-
cemia was signiﬁ  cantly higher with insulin detemir (34%) 
than NPH insulin (25%; p = 0.008). The relative risk (RR) 
of overall and nocturnal hypoglycemia was lower with insu-
lin detemir than NPH insulin (47% and 55% respectively, 
both p   0.01), at equivalent levels of glycemic control 
(Hermansen et al 2006).
These ﬁ  ndings were supported by a further study com-
paring insulin detemir with NPH insulin, in which we also 
considered the timing of the dose in the protocol, ie, a com-
parison of a pre-breakfast and evening dose of once-daily 
insulin detemir. Evening administration of insulin detemir 
was associated with a 65% risk reduction in conﬁ  rmed 
nocturnal episodes versus evening NPH insulin (p   0.05) 
at equivalent HbA1c, with the incidence of nocturnal hypo-
glycemia associated with morning detemir lower still (87%, 
p   0.001) (Philis-Tsimikas et al 2006). No statistically 
signiﬁ  cant differences were obtained between AM and PM 
insulin detemir arms. Overall (24 hour) hypoglycemia was 
reduced by over 50% with evening insulin detemir compared 
with NPH insulin (Philis-Tsimikas et al 2006), suggesting 
a greater tolerability for insulin detemir at equivalent levels 
of glycemic control.
Rosenstock et al (2008) compared insulin detemir with 
insulin glargine in a parallel-group study in 582 insulin-naïve 
adults with type 2 diabetes. Baseline HbA1c was reduced by 
both insulins from 8.6% to 7.2% for insulin detemir and to 
7.1% for insulin glargine (p = ns). Incidence of overall hypo-
glycemia was low (5.8 vs 6.2 episodes per patient year for 
insulin detemir and glargine respectively, p = ns), with inci-
dence of nocturnal hypoglycemia of 1.3 episodes per patient 
year for both, and major hypoglycemia too rare for statistical 
analyses to be performed (Rosenstock et al 2008).
A post-hoc analysis of three trials (Rašlová et al 2004; 
Haak et al 2005; Hermansen et al 2006), which were 22–26 
weeks in duration, demonstrated the same reduced risk in 
hypoglycemia in the elderly (aged   65 years) as in the 
younger age groups (aged 18–64 years), comparing insulin 
detemir with NPH insulin (Garber et al 2007). A risk reduc-
tion of 41% for all hypoglycemic episodes was observed 
with insulin detemir, which was statistically signiﬁ  cant 
(RR = 0.59, p = 0.002, for older persons; RR = 0.75, p = 0.02, 
for younger persons) (Garber et al 2007). This risk reduc-
tion is particularly important, as it may encourage elderly 
patients to adhere to treatment intensiﬁ  cation, as and when 
required.
Two studies have evaluated insulin detemir when used as 
part of a basal–bolus regimen in type 2 diabetes (Haak et al 
2005; Rašlová et al 2004), and compared with NPH insulin. 
Both found that equivalent levels of glycemic control were 
achieved between study insulins, and a similar safety proﬁ  le 
was observed. However, in both studies, two additional ben-
eﬁ  ts were seen in the insulin detemir arm: reduced weight 
gain, and a signiﬁ  cantly lower variation in fasting blood 
glucose (FBG) (Haak et al 2005; Rašlová et al 2004).
Reducing variability
Consistent with data from glycemic clamp studies, insulin 
detemir has been shown in clinical studies of patients with 
type 2 diabetes on basal–bolus therapy to reduce within-
patient variability in plasma glucose levels compared with 
NPH insulin (Table 1). Reductions in variability were 
reported in clinical studies involving basal–bolus regimens 
with insulin detemir, yet this was not always the case for the 
basal plus OAD studies (Philis-Tsimikas et al 2006). This 
inconsistency may be explained by the fact that patients 
treated with basal and OAD therapy are likely to have a 
Table 1 Within-subject variability in type 2 diabetes patients treated 
with insulin detemir in comparison with NPH insulin
Day-to-day variation in self-monitored blood 
glucose levels
Study Insulin detemir NPH insulin p-value
Haak et al 2005 1.3 1.4 0.02
Rašlová et al 2004 1.2 1.5   0.001
Hermansen 
et al 2006a
1.3 1.4   0.001
Philis-Tsimikas 
et al 2006
N/A N/A No signiﬁ  cant 
differences 
observed
aDetermined using pooled pre-breakfast and pre-dinner values.Patient Preference and Adherence 2008:2 327
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greater preservation of endogenous insulin response than 
those treated with basal–bolus, and an ability to regulate 
endogenous insulin secretion may mask between-treatment 
differences in the blood glucose-lowering effects of the 
study insulins.
The clinical implications of reduced blood glucose vari-
ability are, as yet, uncertain; one group found that the coef-
ﬁ  cient of variation of fasting plasma glucose (FPG) was an 
independent predictor of mortality (both all-cause and, in 
particular, cardiovascular mortality) (Muggeo et al 2000). 
However, the relationship between glucose ﬂ  uctuations and 
macrovascular complications remains controversial, and 
is currently under debate (Kilpatrick et al 2006; Hirsch 
and Brownlee 2007; Monnier et al 2007). Recent research 
suggests that the reduced variability in the metabolic effect 
of insulin detemir is strongly associated with a reduced 
incidence of nocturnal hypoglycemia (Niskanen et al 2008), 
consistent with results seen in controlled clinical trials.
Tolerability
Notwithstanding the reduced incidence of hypoglycemia and 
the lower mean weight gain, in clinical trials of patients with 
type 2 diabetes, insulin detemir has been shown to be well 
tolerated, with few adverse events reported and a tolerability 
proﬁ  le similar to other insulins (Rašlová et al 2004; Haak 
et al 2005; Hermansen et al 2006; Philis-Tsimikas et al 2006; 
Rosenstock et al 2008).
Reducing the risk of weight gain
Concern over the potential for weight gain can act as a 
signiﬁ  cant barrier to insulin initiation in patients with type 
2 diabetes (Korytkowski 2002), and can also deter patient 
adherence from intensive therapy required to optimize glyce-
mic control (Polonsky et al 2005). Insulin detemir may help 
patients reach glycemic targets with signiﬁ  cantly less weight 
gain than other insulins (Russell-Jones and Khan 2007).
At equivalent levels of glycemic control, insulin detemir 
has been found to be associated with signiﬁ  cantly less weight 
gain than NPH insulin in a number of clinical trials both 
in basal–OAD regimens (Hermansen et al 2006; Philis-
Tsimikas et al 2006) and when used in basal–bolus therapy 
(Rašlová et al 2004; Haak et al 2005) (Figure 2). Insulin 
detemir also shows lower weight gain when compared with 
insulin glargine; a 1 year study in patients on a basal + OAD 
regimen showed that weight gain in insulin detemir-treated 
patients was signiﬁ  cantly lower when compared with insu-
lin glargine-treated patients (3.0 vs 3.5 kg, p   0.01), and 
patients completing the study on once-daily insulin detemir 
gained the least weight (2.25 kg) (Rosenstock et al 2008).
The reduced weight gain associated with insulin detemir 
compared with other basal insulins appears to have a cor-
relation with body mass index (BMI): the two clinical 
trials comparing insulin detemir with NPH insulin as part 
of basal + OAD therapy both found that, with increasing 
baseline BMI, patients gained less weight with insulin 
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detemir (Hermansen et al 2006; Philis-Tsimikas et al 2006) 
(Figure 3); in both studies, this relationship was not found 
for NPH insulin (p = NS). Thus, insulin detemir may offer a 
weight advantage over NPH insulin, especially in overweight 
or obese people with type 2 diabetes initiating insulin therapy 
(Hermansen et al 2006; Philis-Tsimikas et al 2006).
Phase IV studies
Randomized controlled trials have played an important role 
in assessing the safety and efﬁ  cacy of insulin detemir. How-
ever, it is also important to assess the effectiveness of insulin 
detemir in a real life setting. The PREDICTIVE™ study 
(Predictable Results and Experience in Diabetes through 
Intensiﬁ  cation and Control to Target: An International Vari-
ability Evaluation), is a large, open-label, non-randomized, 
non-interventional study, carried out in a diverse population 
primarily to evaluate the safety and efﬁ  cacy of insulin detemir 
as part of routine clinical care (Lüddeke et al 2007). This 
multinational study has recruited, so far, as many as 40,000 
patients, who have been followed for 12, 26 or 52 weeks, 
depending on country.
Data recorded for patients participating in PREDIC-
TIVE™ for 12 weeks have been recently published (Dornhorst 
et al 2007; Dornhorst et al 2008a; Dornhorst et al 2008b). Patient Preference and Adherence 2008:2 329
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The PREDICTIVE™ study included a large cohort of patients 
who were insulin-naïve prior to starting a regimen with 
insulin detemir (Dornhorst et al 2008a). Glycemic control 
improved signiﬁ  cantly; mean HbA1c was reduced from 8.9% 
to 7.6% (−1.3%; p   0.0001) and mean fasting glucose 
and within-patient fasting glucose variability was reduced 
by −3.7 and −0.5 mmol/L, respectively (p   0.0001). This 
was achieved in association with a low risk of hypoglyce-
mia; the incidence of total, major and nocturnal episodes 
was low, with a slight reduction in incidence (baseline fre-
quency:endpoint frequency): −0.3 (1.4–1.2), −0.1 (0.1–0.0), 
−0.1 (0.4–0.3) episodes per patient year, for total, major and 
nocturnal hypoglycemia, respectively. A statistically signiﬁ  -
cant decrease in mean body weight (−0.7 kg; p   0.0001) 
was also reported in these previously insulin-naïve patients. 
As observed in clinical trials, mean weight change (kg) had 
a statistically signiﬁ  cant inverse relationship with BMI, in 
which patients with the highest BMI (BMI   31 kg/m2) 
experienced the greatest reduction in weight (−1.51 kg) 
(Dornhorst et al 2008a).
Patients switching from their previous basal insulin to 
insulin detemir experienced improvements in glycemic 
control: in the previously NPH insulin-treated group, mean 
HbA1c was reduced by −0.2% (p   0.05) and by −0.6% 
(p   0.0001) among patients switching from insulin glargine. 
The improvements in glycemic control were accompanied by 
signiﬁ  cant reductions in hypoglycemia. Patients switching 
from NPH insulin and insulin glargine to insulin detemir had 
signiﬁ  cant decreases in the incidence of total hypoglycemia 
from 11.7 to 3.0 episodes/patient-year (p   0.001) and from 
4.3 to 0.8 episodes/patient-year (p   0.01), respectively. 
Nocturnal hypoglycemia was also signiﬁ  cantly reduced by 
81% in patients switching from NPH insulin and by 75% in 
patients switching from insulin glargine (Figure 4). Switching 
to insulin detemir also resulted in a weight-sparing effect as 
mean body weight was reduced by 0.7 kg in NPH insulin 
switchers (p   0.01) and by 0.5 kg in insulin glargine switch-
ers (p   0.05) (Dornhorst et al 2008b).
Insulin detemir in a primary 
care setting
Insulin initiation and treatment is increasingly managed in 
a primary care setting. The PREDICTIVE™ 303 trial was a 
prospective trial of insulin detemir carried out predominantly 
in primary care practices in the USA (Meneghini et al 2007; 
Selam et al 2008). It compared a simpliﬁ  ed patient-adjusted 
dosing algorithm (303) with a standard of care physician-
driven adjustment in individuals with type 2 diabetes. 
All patients in the study were switched to, or started on, 
once-daily insulin detemir as their basal insulin replace-
ment. Patients were randomized and the starting doses were 
0.32 U/kg, and 0.34 U/kg for the 303 and standard of care 
groups, respectively. The 303 algorithm group was instructed 
to use a simple algorithm to adjust their insulin detemir dose 
every 3 days based on three self-measured FBG values:
•  Patients reduced their insulin dose by 3 units if 
FBG   80 mg/dL (  4.4 mmol/L);
•  Patients made no change to their current insulin dose if 
FBG was between 80–110 mg/dL (4.4–6.1 mmol/L);
•  Patients increased their insulin dose by 3 units if 
FBG   110 mg/dL (  6.1 mmol/L).
Insulin adjustments in the standard of care group were 
made by the physician. A signiﬁ  cant difference in reduc-
tion in HbA1c was observed in favor of the 303 algorithm 
group (p = 0.016), although the reductions from baseline 
(8.5% for both groups) to endpoint (7.9 vs 8.0%) were of 
clinically similar magnitude. Despite similarities in HbA1c 
reductions, the mean FPG reduction was signiﬁ  cantly greater 
in the 303 algorithm group than the standard of care group; 
1.8 mmol/L vs 1.2 mmol/L, respectively (p   0.0001). Overall 
hypoglycemia was reduced in both groups by 2.61 from 9.53 
events/patient-year and by 4.58 from 9.05 events/patient-year 
in the 303 algorithm and the standard of care group, respec-
tively. Both patient groups had no signiﬁ  cant weight gain after 
26 weeks of treatment. Interestingly, an analysis of the entire 
PREDICTIVE™ 303 cohort further suggested a relationship 
between BMI and weight gain; on average, patients with a 
higher BMI (BMI   30 kg/m2) treated with insulin detemir lost 
weight during the study, whilst patients at the lower end of the 
BMI spectrum (  2 5 kg/m2) experienced modest weight gain 
(Meneghini et al 2007; Selam et al 2008). This observation 
is consistent with data from clinical trials (Hermansen et al 
2006; Philis-Tsimikas et al 2006) and the PREDICTIVE™ 
study (Dornhorst et al 2007; Dornhorst et al 2008a, b).
Overall, PREDICTIVE™ 303 successfully demonstrated 
patients’ ability to adjust their basal insulin dose according to 
a simple dosing algorithm, and to be as effective in this respect 
as physician-directed dose adjustment. Both methods of adjust-
ment were equally successful at reducing HbA1c and FPG 
without increasing the risk of hypoglycemia, suggesting that a 
patient-driven method may be a safe and effective alternative 
to the physician-directed adjustment of insulin detemir.
Insulin detemir delivery
A reported 51%–79% of patients adhere to their insulin 
therapy; this percentage decreases as the complexity of Patient Preference and Adherence 2008:2 330
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the regimen increases (Claxton et al 2001). Adherence to 
a prescribed therapeutic regimen is strongly inﬂ  uenced 
by the convenience and simplicity of the dosing regimen 
(Korytkowski 2002).
A common issue that affects patient adherence, par-
ticularly for new insulin users, is a reluctance to self-inject. 
Even conﬁ  dent patients would, naturally, prefer a painless 
and simple insulin delivery method. Insulin detemir is avail-
able for use with a vial and syringe, but also in two types of 
insulin delivery pen: NovoPen®, a reusable insulin pen, and 
FlexPen®, a disposable pen. Both pens have been designed 
to facilitate greater patient acceptance, and a series of con-
trolled trials have demonstrated that both devices improve 
patient satisfaction.
Modern basal insulins can only be effectively employed 
if dose delivery is accurate: achieving a reliable and cor-
rect dose of insulin is a key concern for both patients and 
physicians (Peyrot et al 2005). Up to 80% of people with 
diabetes incorrectly administer insulin when using a syringe 
(Korytkowski et al 2005). Previous studies have shown that 
patients using a vial and syringe are more likely to draw and 
inject an inaccurate dose, particularly when only small doses 
are required (Casella et al 1993; Lteif and Schwenk 1999).
Pen devices offer features which may minimize dosing 
inaccuracies during administration. For example, in a study 
by Korytkowski et al (2003), 85% (89/105) of patients found 
it easier to read the insulin dose scale than with a conventional 
vial and syringe. Furthermore, 82% (86/105) of patients were 
reported more conﬁ  dent in setting the required dose, in con-
trast with only 11% (12/105) with the vial and syringe. As a 
result, 73% (77/105) of patients felt more conﬁ  dent with the 
accuracy of the insulin dose with a pen device compared with 
19% (20/105) for vial/syringe (Korytkowski et al 2003).
Recent developments in insulin pens have proven popular 
with patients with regard to usability, convenience, percep-
tions of safety and trust and overall preference (Sommavilla 
et al 2008).
It is essential to maintain accuracy (within ISO recom-
mendations) with the injection device as not to compro-
mise glycemic control and lose patient conﬁ  dence in their 
regimen.
Summary
When compared with older basal insulins, insulin detemir 
provides effective glycemic control, reduced variability in 
blood glucose-lowering response, less weight gain and a 
reduction in the number of hypoglycemic events, especially 
for nocturnal hypoglycemia. These results are supportive of 
the use of once-daily insulin detemir; dose adjustments of 
which have been made simpler by improvements in injection 
devices, and the development of simple, patient-friendly algo-
rithms. Insulin detemir therefore provides a treatment option 
with the potential to lower the key barriers to acceptance of 
and adherence to insulin therapy in type 2 diabetes.
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